In this online CME self-learning program:
Migraine headache is the leading condition of recurrent cephalalgias of moderate or severe intensity. It is the most common type of headache presented by patients that seek medical treatment, and the World Health Organization (WHO) has ranked migraine in the top fifteen most disabling medical conditions. The condition has been identified as one of the most common neurological disorders, and in the United States, its prevalence in the general population is approximately 12%. In children, the prevalence ranges from 1% to 4% and does not present more commonly in either sex. However, after menarche, its prevalence in females (18%) is approximately three times higher than in males.
Moreover, professional guidelines relating to the classification, diagnosis, prophylaxis, and treatment of migraine headaches have been updated recently, and communicating related information to healthcare professionals in a timely manner is a demonstrated need. The literature suggests that practicing healthcare professionals are often times unable to keep up with the steady publishing of literature and evolution of clinical practice, and awareness of professional guidelines is no exception. Recently published guidelines therefore also inherently suggest a gap in medical practice and justify the need for educational programming. Generalists may be at particular risk for missing updates in standards relating to migraine subtypes like menstual and abdominal migraines.
Neurologists and any other healthcare professionals who otherwise come into regular clinical contact with and provide care for patients with migraine.
This program is supported by an educational grant from Amgen.
This activity is free of charge.
Release Date: August 08, 2020 -- Expiration Date: August 08, 2022
Faculty: Stewart Tepper, MD
Generally an annual scientific meeting is a buffet of new information and trial presentations, lectures on the cutting edge of the scientific developments in the therapeutic field, industry supplied information, and networking. The AHS Virtual Annual Scientific Meeting was a necessarily shortened set of lectures, platform presentations, and abstracts, all reduced in lecture time due to the web-based format, and those finally selected were of the top quality. Still, the meeting remained a smorgasbord, from which to select the most interesting and useful material:
By the end of the session the participant will be able to:
ACCME Activity #201540535ACCREDITATION FOR THIS COURSE HAS EXPIRED. YOU MAY VIEW THE PROGRAM, BUT CME / CE IS NO LONGER AVAILABLE AND NO CERTIFICATE WILL BE ISSUED.
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Stewart J. Tepper, MD, Director, Dartmouth Headache Center, Professor of Neurology, Geisel School of Medicine at Dartmouth, discloses that he has received financial compensation from consulting, ownership interest and/or advisory board work from: Acorda, Aeon, Alexsa, Align Strategies, Allergan, Alphasights, Amgen, Aperture Venture Partners, Aralez Canada, Axsome Therapeutics, Becker Pharmaceutical Consulting, BioDelivery Sciences International, Biohaven, Charleston Labs, CRG, DeepBench, Dr. Reddy’s, ElectroCore, Eli Lilly, eNeura, Equinox, ExpertConnect, GLG, GSK. Guidepoint Global, Healthcare Consultancy Group, Health Sciences Communications, Impel, Lundbeck, M3 Global Research, Magellan Rx Management, Marcia Berenson Connected Research and Consulting, Medicxi, Navigant Consulting, Neurolief, Mocira, Nordic BioTech, Novartis, Pulmatrix, Percept, Reckner Healthcare, Relevale, Revance, SAI Medical Partners, Satsuma, Scion Neurostim, Slingshot Insights, Sorrento, Spherix Global Insights, Sudler and Hennessey, Synapse Medical Communications, Teva, Theranica, Trinity Partners, XOC, and Zosano.
Disclosures of Educational Planners: Charles Turck, PharmD, CEO of ScientiaCME, has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Amgen.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Chronic inflammatory demyelinating polyneuropathy (CIDP): Optimizing pharmacotherapeutic management strategies
Alzheimer Disease and Its Complications: Best Practices, Emerging Therapies, and Barriers to Care
Coronavirus disease 2019 (COVID-19) preparedness, facts, and management